Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer

Cancer

Volumn 115, Issue 3, 2009, Pages 489-498

  Le, Quang A ^a   Hay, Joel W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Advanced breast cancer; Cost effectiveness analysis; Cost utility analysis; Economics; HER 2; ICER; Lapatinib; Metastatic breast cancer; Tykerb

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CASE REPORT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; FEMALE; HEALTH CARE COST; HUMAN; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE; QUINAZOLINES; SENSITIVITY AND SPECIFICITY;

EID: 60049099370     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24033     Document Type: Article

References (29)

1. American Cancer Society. Breast Cancer Facts & Figures 2007-2008. Atlanta, GA: American Cancer Society, 2007.
2. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute. Based on November 2006 SEER data submission, posted to the SEER website 2007. Available at: http://seer.cancer.gov/csr/1975-2004 Accessed on December 17, 2007.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
4. Muss HB. Targeted therapy for metastatic breast cancer. N Engl J Med. 2006;355:2783-2785.
5. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2 - positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
6. Geyer CE, Martin A, Newstat B, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data [abstract]. J Clin Oncol. 2007;25:18S.
7. An open-label, multicenter, single arm phase II study of oral GW572016 as single agent therapy in subjects with advanced or metastatic breast cancer who have progressed while receiving Herceptin containing regimens. GlaxoSmithKline. Available at: http://ctr.gsk.co.uk/Summary/lapatinib/II-EGF20002.pdf Accessed December 18, 2007.
8. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"): II. Use in medical decision-making. Am J Med. 1982;73:889-997.
9. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost- Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
10. National Institute for Health and Clinical Excellence. Breast cancer (advanced or metastatic) - lapatinib. Appraisal consultation document. Available at: http://www.nice.org.uk/guidance/index.jsp?action=article& o=41153 Accessed: May 15, 2008.
11. Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007;110:489-498.
12. Dranitsaris G,Maroun J,Shah A. Severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer: a cost of illness analysis [abstract]. J Clin Oncol. 2004;22:14S.
13. Shah A, Maroun J, Dranitsaris G. The cost of hospitalization secondary to severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer [abstract]. J Clin Oncol. 2004:22:14S.
14. Centers for Medicare and Medicaid. Available at: http://www.cms.hhs.gov/ home/medicare.asp Accessed August 31, 2007.
15. McLachlan SA, Pintilie M, Tannock IF. Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost. Breast Cancer Res Treat. 1999;54:213-223.
16. Pelletier EM, Shim B, Goodman S, Amonkar MM. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat. 2008;108:297-305.
17. US Department of Labor: US Bureau of Labor Statistics. Available at: http://www.bls.gov Accessed July 21, 2007.
18. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22:854-863.
19. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-3317.
20. Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti-cancer Drugs. 1998;9:899-907.
21. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6:52.
22. Ubel PA, Hirth RA, Chernew ME, Fendick M. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.
23. Devlin N, Parkin D. Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437-452.
24. Lamers LM, Stupp R, van den Bent MJ, et al. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008; 112:1337-1344.
25. Extra J-M, Antoine E-C, Vincent-Salomon A, et al. Favourable effect of continued trastuzumab treatment in metastatic breast cancer: results from the French Hermine cohort study. Breast Cancer Res Treat. 2006;100:S102.
26. Bartsch R, Wenzel C, Altorjai G, et al. Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC) [abstract]. J Clin Oncol. 2007;25:18S.
27. Garcia-Saenz JA, Martin M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer. 2005;6:325-329.
28. Del Bianco S, Rondinelli R. Trastuzumab-containing therapies: activity beyond disease progression in M.B.C. - A pivotal experience [abstract]. J Clin Oncol. 2006;24:18S.
29. Morabito A, Longo R, Gattuso D, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second- line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep. 2006;16:393-398.